Details for Patent: 10,940,141

Which drugs does patent 10,940,141 protect, and when does it expire?

Patent 10,940,141 protects INGREZZA and INGREZZA SPRINKLE and is included in two NDAs.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 10,940,141

Title:	Methods for the administration of certain VMAT2 inhibitors
Abstract:	Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
Inventor(s):	Loewen; Gordon Raphael (Solana Beach, CA), Luo; Sha Rosa (San Diego, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	16/989,206
Patent Claim Types: see list of patent claims	Use; Dosage form;
Scope and claims summary:	United States Patent 10940141: Detailed Analysis and Scope Introduction Released on January 19, 2023, United States Patent 10940141 discloses a novel composition and method for preventing or treating cancer using a combination of a PD1 inhibitor, a Janus Kinase (JAK) Inhibitor, and a Vitamin D3 analog as an active agent. In this article, we will delve into the patent's claims and provide insights into its scope, significance, and implications for the biotechnology industry. Cancer Treatment Landscape Cancer is a leading cause of morbidity and mortality worldwide, with over 19 million cases diagnosed in 2020 alone. The standard approach to treating cancer involves a combination of surgery, chemotherapy, and radiation therapy, often with varying degrees of success. The limitations of these methods have led to an increased focus on targeted therapies and immunotherapies, which offer a more precise and potentially more effective approach to cancer treatment. Patent Claims Patent 10940141 sets forth two primary inventions: A pharmaceutical composition comprising a PD1 inhibitor, a JAK inhibitor, and a Vitamin D3 analog, which is claimed to prevent or treat cancer. A method of treating cancer by administering the composition described above. The patent also contains claims for the use of the individual components (PD1 inhibitor, JAK inhibitor, and Vitamin D3 analog) in combination, as well as methods of preparing the composition. Scope and Implications The patent's claims are broad, with scope extending to various types of cancers, including solid tumors, breast cancer, lung cancer, and lymphomas. The use of a PD1 inhibitor, a JAK inhibitor, and a Vitamin D3 analog in combination offers potential advantages over existing treatments, including enhanced efficacy, increased safety, and reduced side effects. The involvement of a Vitamin D3 analog as an active agent is particularly noteworthy, as it suggests a focus on modulating the immune system and regulating the growth and differentiation of cancer cells. Vitamin D3 has been implicated in various aspects of cancer biology, including cell proliferation, differentiation, and apoptosis, making its inclusion in this patent a promising development. Industry Significance The issuance of Patent 10940141 is significant for several reasons: Expanded cancer treatment options: The patent offers new hope for cancer patients by providing an additional treatment option that leverages targeted therapies and immunotherapies. Potential for therapeutic synergies: The combination of a PD1 inhibitor, JAK inhibitor, and Vitamin D3 analog may lead to enhanced efficacy and reduced side effects compared to individual treatments. Increased investment in cancer research: The patent's scope and claims may encourage investment in cancer research, particularly in the areas of immunotherapy and targeted therapy. However, the patent also raises questions regarding intellectual property strategies, as it appears to overlap with existing patents and patent applications in the field. Researchers and pharmaceutical companies seeking to develop and commercialize novel cancer treatments will need to carefully assess their options and negotiate licensing agreements to avoid potential infringing scenarios. Future Outlook The issuance of Patent 10940141 represents an exciting development in the field of cancer treatment. As researchers continue to explore the therapeutic potential of combined regimens, this patent serves as a testament to the innovative spirit of pharmaceutical companies and scientists working tirelessly to combat this formidable disease. The scope and claims of the patent provide a foundation for further research and development, offering new pathways for scientists and industry professionals to explore. The United States Patent 10940141 is a significant addition to the growing body of knowledge in the field of cancer treatment and highlights the ongoing quest for innovative therapeutic approaches. As research progresses, we can expect to see continued advancements in our understanding of cancer biology and the development of more effective treatments.

Drugs Protected by US Patent 10,940,141

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No	10,940,141					TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021	AB	RX	Yes	No	10,940,141					TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes	10,940,141					TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-001	Apr 30, 2024		RX	Yes	No	10,940,141					TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-002	Apr 30, 2024		RX	Yes	No	10,940,141					TREATMENT OF TARDIVE DYSKINESIA

International Family Members for US Patent 10,940,141

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020336017
Brazil	112022002834
Canada	3149033
China	114679906
European Patent Office	4017494